HEUKING advises Vidac Pharma Holding PLC on listing on the Primary Market of Düsseldorf Stock Exchange and public offering

HEUKING legally advised London-based Vidac Pharma Holding PLC on the inclusion of its shares in trading on the Open Market of Düsseldorf Stock Exchange, in the Primary Market segment, as well as on the public offering of shares and the drafting of the related securities prospectus. 

On December 1, 2025, all 56,946,204 ordinary shares of the company were admitted to trading on Düsseldorf Stock Exchange. The shares are included in the Primary Market segment, which is characterized by enhanced transparency requirements and is particularly attractive for growth-oriented companies with capital market ambitions. In connection with the inclusion, Dr. Max Herzberg, founder, director, and major shareholder, is offering 50,000 shares from his portfolio in a public offering conducted exclusively in Germany via Düsseldorf Stock Exchange. 

Vidac Pharma Holding PLC is the holding company of Vidac Pharma Ltd., an Israel incorporated clinical-stage biopharmaceutical company dedicated to developing novel therapies for cancer and oncodermatological diseases. Vidac Pharma Ltd. is developing drug candidates for the treatment of various indications, including cancer, skin cancer and solid tumors. The listing strengthens Vidac Pharma Holding PLC’s presence on the German capital market and offers investors the opportunity to participate in an innovative company in pharmaceutical research and development. 

The client was legally advised by a team led by HEUKING Partner Dr. Mirko Sickinger, LL.M., jointly with Salaried Partner Sven Radke, LL.M. and Franziska Marisa Decker, M.A.

Counsel to Vidac Pharma Holding PLC
HEUKING:
Dr. Mirko Sickinger, LL.M. (Columbia University),
Sven Radke, LL.M. (London Metropolitan University),
Franziska Marisa Decker, M.A. (Business for Legal Professionals), all Capital Markets, all Cologne